News Archive

October 2016

• Press Release Oct 25, 2016

  Novartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentiels

  Chiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa…
• Press Release Oct 17, 2016

  Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting

  Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle…
• 
  Story Oct 13, 2016 Discovery

  The Evolution of a Scientist

  A middle school student curious about science grows into a college-bound scientist.

• 
  Story Oct 13, 2016 Discovery

  Women in Science: Tania Small

  Meet a Senior Medical Director at Novartis who is part of our new “Women in Science” series

• 
  Story Oct 13, 2016 Access to Healthcare

  New Orbis Flying Eye Hospital helps fight blindness in China

  During a three-week maiden voyage to the northern city of Shenyang, the plane's medical volunteers treated 124 patients and provided hands-on surgical training to 18 local doctors.

• Press Release Oct 09, 2016

  Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study

  Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…
• Press Release Oct 08, 2016

  Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up

  Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
• Press Release Oct 08, 2016

  Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

  LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…
• 
  Story Oct 05, 2016 Discovery

  Chan Zuckerberg Initiative friends Novartis scientist in mission to conquer disease

  Novartis’ Don Ganem tapped as a scientific advisor for the Chan Zuckerberg Biohub

• 
  Story Oct 03, 2016 From Our Labs

  Improving science communication in 3 easy steps

• 
  Story Oct 03, 2016 Patient Perspectives

  Digital health: providing opportunities for advocacy groups and a community for patients

  Learn about how digital is changing the face of patient advocacy.

• Press Release Oct 03, 2016

  Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey

  Global survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment[1]* Majority (84%) face…